RecruitingNot Applicable

Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects

Australia15 participantsStarted 2025-11-12

Plain-language summary

To assess subject-centric real-world evidence of QoL outcomes in subjects enrolled in the global Phase 3 AU-011-301 clinical trial.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Have enrolled in the Aura-sponsored clinical trial AU-011-301. * Access to a connected device (i.e., smartphone, laptop, or tablet) Exclusion Criteria: * None

What they're measuring

Change from baseline in EORTC QLQ-C30 scores at month 15 and 24.

Timeframe: 24 months

Trial details

NCT IDNCT07421739

SponsorAura Biosciences

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2028-08-15

Contact for this trial

Medical Monitor

617-500-8864 clinical@aurabiosciences.com

View on ClinicalTrials.gov More Choroidal Melanoma trials